BetterLife Pharma (TSE:BETR) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
BetterLife Pharma Inc. has amended beneficial ownership information in past Management Information Circulars and announced the issuance of new shares and warrants following a convertible debentures conversion. The biotech company is advancing the development of non-hallucinogenic compounds, BETR-001 and BETR-002, aimed at treating various neuropsychiatric and neurological disorders.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
